Intelligence · Clinical Development
Pipeline search results
Programs matching “Pharma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 4,472 pipeline programs matching "Pharma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ION775
IONIS PHARMACEUTICALS INC
Hypertriglyceridemia
1 trial -
ION904
IONIS PHARMACEUTICALS INC
Hypertension
1 trial -
IONIS DGAT2Rx
IONIS PHARMACEUTICALS INC
Hepatic Steatosis
1 trial -
IONIS GHR-LRx
IONIS PHARMACEUTICALS INC
Acromegaly
2 trials -
IONIS-AGT-LRx
IONIS PHARMACEUTICALS INC
Chronic Heart Failure With Reduced Ejection Fraction
1 trial -
IONIS-DMPKRx
IONIS PHARMACEUTICALS INC
Myotonic Dystrophy Type 1
1 trial -
IONIS-FB-LRx
IONIS PHARMACEUTICALS INC
Macular Degeneration
1 trial -
IONIS-FB-LRx
IONIS PHARMACEUTICALS INC
Primary IgA Nephropathy
1 trial -
IONIS-FB-Lrx
IONIS PHARMACEUTICALS INC
Geographic Atrophy
1 trial -
IONIS-HBVRx
IONIS PHARMACEUTICALS INC
Hepatitis B
1 trial -
IONIS-PKKRx (ISIS 546254)
IONIS PHARMACEUTICALS INC
Chronic Migraine
1 trial -
IONIS-STAT3Rx
IONIS PHARMACEUTICALS INC
Advanced Cancers
1 trial -
IPH5201-201
Lacuna Pharma Pty Ltd
Non-Small Cell Lung Cancer II, III
1 trial -
IPH6501
Lacuna Pharma Pty Ltd
Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
1 trial -
IR Viloxazine
SUPERNUS PHARMACEUTICALS, INC.
Attention-Deficit/Hyperactivity Disorder (ADHD)
1 trial -
IR-TPM (Topamax)
SUPERNUS PHARMACEUTICALS, INC.
Migraine
1 trial -
IRINOTECAN, lurbinectedin
Lacuna Pharma Pty Ltd
Selected Advanced Solid Tumors
1 trial -
ISATUXIMAB
Pari Pharma GmbH
Isatuximab in type I cryoglobulinaemia: A prospective pilot study
1 trial -
ISIS 104838
IONIS PHARMACEUTICALS INC
Rheumatoid Arthritis
1 trial -
ISIS 113715
IONIS PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
5 trials -
ISIS 14803
IONIS PHARMACEUTICALS INC
Hepatitis C, Chronic
1 trial -
ISIS 14803-CS3
IONIS PHARMACEUTICALS INC
Hepatitis C, Chronic
1 trial -
ISIS 2503
IONIS PHARMACEUTICALS INC
Pancreatic Cancer
1 trial -
ISIS 301012
IONIS PHARMACEUTICALS INC
Hypercholesterolemia, Familial
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.